212 related articles for article (PubMed ID: 28810946)
1. Safety and Efficacy of Rotigotine for Treating Parkinson's Disease: A Meta-Analysis of Randomised Controlled Trials.
Chen F; Jin L; Nie Z
J Pharm Pharm Sci; 2017; 20(0):285-294. PubMed ID: 28810946
[TBL] [Abstract][Full Text] [Related]
2. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
[TBL] [Abstract][Full Text] [Related]
3. Transdermal rotigotine in early stage Parkinson's disease: a randomized, double-blind, placebo-controlled trial.
Mizuno Y; Nomoto M; Kondo T; Hasegawa K; Murata M; Takeuchi M; Ikeda J; Tomida T; Hattori N;
Mov Disord; 2013 Sep; 28(10):1447-50. PubMed ID: 23801585
[TBL] [Abstract][Full Text] [Related]
4. Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson's disease with mild symptom severity.
Timmermann L; Asgharnejad M; Boroojerdi B; Dohin E; Woltering F; Elmer LW
Expert Opin Pharmacother; 2015; 16(10):1423-33. PubMed ID: 25997442
[TBL] [Abstract][Full Text] [Related]
5. Rotigotine transdermal patch in Chinese patients with early Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study.
Zhang ZX; Shang HF; Hu X; Chen S; Zhao Z; Du X; Surmann E; Bauer L; Asgharnejad M
Parkinsonism Relat Disord; 2016 Jul; 28():49-55. PubMed ID: 27172830
[TBL] [Abstract][Full Text] [Related]
6. Rotigotine transdermal system for the treatment of Parkinson's disease.
Pham DQ; Nogid A
Clin Ther; 2008 May; 30(5):813-24. PubMed ID: 18555929
[TBL] [Abstract][Full Text] [Related]
7. The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease.
Giladi N; Boroojerdi B; Surmann E
J Neural Transm (Vienna); 2013 Sep; 120(9):1321-9. PubMed ID: 23508526
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study.
Elmer LW; Surmann E; Boroojerdi B; Jankovic J
Parkinsonism Relat Disord; 2012 Jun; 18(5):488-93. PubMed ID: 22326237
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.
Giladi N; Nicholas AP; Asgharnejad M; Dohin E; Woltering F; Bauer L; Poewe W
J Parkinsons Dis; 2016 Oct; 6(4):741-749. PubMed ID: 27567886
[TBL] [Abstract][Full Text] [Related]
10. Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis.
Zhou CQ; Li SS; Chen ZM; Li FQ; Lei P; Peng GG
PLoS One; 2013; 8(7):e69738. PubMed ID: 23936090
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis evaluating effects of the rotigotine in Parkinson's disease, focusing on sleep disturbances and activities of daily living.
Sun W; Wang Q; Yang T; Feng C; Qu Y; Yang Y; Li C; Sun Z; Asakawa T
Neurol Sci; 2022 Oct; 43(10):5821-5837. PubMed ID: 35691972
[TBL] [Abstract][Full Text] [Related]
12. A controlled trial of rotigotine monotherapy in early Parkinson's disease.
Parkinson Study Group
Arch Neurol; 2003 Dec; 60(12):1721-8. PubMed ID: 14676046
[TBL] [Abstract][Full Text] [Related]
13. A randomized study of rotigotine dose response on 'off' time in advanced Parkinson's disease.
Nicholas AP; Borgohain R; Chaná P; Surmann E; Thompson EL; Bauer L; Whitesides J; Elmer LW;
J Parkinsons Dis; 2014; 4(3):361-73. PubMed ID: 24643203
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson's disease.
Chung SJ; Asgharnejad M; Bauer L; Ramirez F; Jeon B
Expert Opin Pharmacother; 2016 Aug; 17(11):1453-61. PubMed ID: 27322571
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease.
Hauser RA; Slawek J; Barone P; Dohin E; Surmann E; Asgharnejad M; Bauer L
BMC Neurol; 2016 Jun; 16():90. PubMed ID: 27267880
[TBL] [Abstract][Full Text] [Related]
16. Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study.
Kim JM; Chung SJ; Kim JW; Jeon BS; Singh P; Thierfelder S; Ikeda J; Bauer L;
BMC Neurol; 2015 Feb; 15():17. PubMed ID: 25879416
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on rotigotine transdermal patch in Parkinson's disease.
Sanford M; Scott LJ
Drugs Aging; 2011 Dec; 28(12):1015-7. PubMed ID: 22117099
[TBL] [Abstract][Full Text] [Related]
18. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
Splinter MY
Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
[TBL] [Abstract][Full Text] [Related]
19. Rotigotine transdermal patch in Chinese patients with advanced Parkinson's disease: A randomized, double-blind, placebo-controlled pivotal study.
Zhang ZX; Liu CF; Tao EX; Shao M; Liu YM; Wang J; Asgharnejad M; Xue HB; Surmann E; Bauer L
Parkinsonism Relat Disord; 2017 Nov; 44():6-12. PubMed ID: 28827011
[TBL] [Abstract][Full Text] [Related]
20. Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial.
Antonini A; Bauer L; Dohin E; Oertel WH; Rascol O; Reichmann H; Schmid M; Singh P; Tolosa E; Chaudhuri KR
Eur J Neurol; 2015 Oct; 22(10):1400-7. PubMed ID: 26095948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]